TOMAC Therapy for Restless Legs Syndrome
Tonic motor activation (TOMAC) is a noninvasive, wearable electrical stimulation therapy for moderate to severe restless legs syndrome.
Tonic motor activation (TOMAC) is a prescription-only therapy for moderate to severe restless legs syndrome (RLS). The wearable device, which became billable under dedicated Medicare codes in October 2024, delivers electrical stimulation to nerves in the lower legs to mimic the relief of voluntary movement.
According to a report from the American Academy of Sleep Medicine's Coding and Reimbursement Advisory Committee, TOMAC involves bilateral peroneal nerve stimulation. The high-frequency stimulation activates the tibialis anterior muscle, causing low-intensity contractions. The therapy's proposed mechanism is that this generates sensory feedback to the central nervous system, potentially modulating the abnormal neural pathways responsible for RLS symptoms.
Documentation Requirements for Medical Necessity
To secure coverage, clinicians must document several key elements. A confirmed diagnosis of primary RLS is required, ideally with a validated severity score. One current payer policy specifies an International Restless Legs Syndrome (IRLS) Rating Scale score of 15 or greater, indicating moderate to severe disease. This aligns with common requirements found in payer stats and policies.
The patient must be refractory to medications. Documentation should show failure or intolerance to one or more drug classes, such as gabapentin, dopamine agonists, or opioids. Reversible exacerbating factors must also be addressed. Policies commonly require assessment and management of issues like iron deficiency, caffeine use, antidopaminergic drugs, or untreated obstructive sleep apnea.
Symptom patterns must justify therapy. Notes should indicate symptoms occur predominantly in the lower legs or feet, usually in the evening or night, with a frequency of at least two nights per week per one policy. Contraindications must be ruled out, including epilepsy, active implanted devices, or skin issues at the application site. Finally, for ongoing coverage, documentation must show a measurable decrease in RLS symptoms with consistent device use, a key metric for tracking therapeutic standings.
Billing Codes and Distinctions
The Centers for Medicare & Medicaid Services (CMS) established two specific Healthcare Common Procedure Coding System (HCPCS) codes for TOMAC, effective October 1, 2024. No Current Procedural Terminology (CPT) codes apply, as the treatment is not a billable physician procedure.
| HCPCS Code | Description | Use Case |
|---|---|---|
| E0743 | Wearable electrical stimulator device for tonic motor activation therapy | Billing the TOMAC device itself |
| A4544 | Supplies for use with tonic motor activation therapy | Billing associated disposable or replenishable supplies |
The committee emphasizes that invasive peripheral nerve stimulation CPT codes are not appropriate for this noninvasive, wearable therapy. Billing is handled under the durable medical equipment (DME) benefit.
Common Billing Pitfalls and Coverage Challenges
Several operational pitfalls can lead to claim denials. Using incorrect codes is a primary risk. Staff must use the product-specific codes E0743 and A4544, not generic electrical stimulation codes like 97014 or G0283.
Understanding unit billing is critical. Code E0743 is billed per unit, with one unit representing one device. Therefore, two units are required for bilateral leg treatment. CMS has classified TOMAC as a capped rental item under DME rules, not a one-time supply or implanted device.
Insufficient documentation is a major cause of denial. The chart must clearly show persistent symptoms, a failed medication history, and that reversible factors were addressed. Coverage remains inconsistent across payers. Some plans require prior authorization, while others still consider TOMAC investigational. The report advises always reviewing plan-specific policies and preparing for appeals. Contraindications like untreated sleep apnea or peripheral neuropathy can also lead to coverage denials or clinical deferral.
The committee provided a use case example: a 66-year-old Medicare beneficiary with a 10-year RLS history, hypertension, and Type 2 diabetes. For such a patient, a sleep physician would review the treatment history, confirm severity with the IRLS scale, evaluate contraindications, and if appropriate, prescribe TOMAC. The appropriate codes for billing would be E0743 for the device and A4544 for supplies, with no time-based procedure code reported.
